Multimodal imaging and artificial intelligence for response assessment to neoadjuvant therapy in breast cancer: a
Linlin Shao1, Mingyu Zhang2, Lili Zhang1
1Ultrasound Diagnostic Center, The First Hospital of Jilin University, Changchun, China.
NPJ Breast Cancer
|June 24, 2026
Abstract:
This narrative review explores the latest advancements in various imaging modalities combined with artificial intelligence (AI) for monitoring response to neoadjuvant therapy (NT) and predicting pathological complete response (pCR). We provide a detailed analysis of the principles, evaluation metrics, strengths, and limitations of each technique. The integration of multimodal imaging and AI is reshaping the paradigm for evaluating NT efficacy in breast cancer, offering robust support for precision medicine.

